Other secondary endpoints
GNEM-FAS upper extremity score did not change remarkably until Week 36 and was slightly decreased at Week 48 in the SA-ER group, in contrast to a clear decline at Week 12 and subsequently in the placebo group (Fig. Mean and SD plots of change from baseline in GNEM-FAS upper extremity score (FAS). FAS, full analysis set; GNEM-FAS, GNE myopathy-Functional Activity Scale; SA-ER, sialic acid extended-release; SD, standard deviationMean and SD plots of change from baseline in other scores of GNEM-FAS (FAS). 